The results come from a phase-III study that included data from 44 men with prostate cancer who underwent transrectal MRgFUS between February 2016 and July 2019. Of these, 36 had Gleason grade group 2 disease and eight had grade group 3 -- both groups that indicate intermediate disease. The men were followed up with multiparametric MRI and biopsy at six and 24 months; they were also assessed for prostate cancer symptoms and erectile function at 24 months. None of them experienced complications from the MRgFUS procedure.
The investigators found that 91% of the men were free of disease at the treatment site at 24-month follow-up, and median symptom/erectile function scores at two years post-treatment were similar to baseline scores. The findings suggest that "targeted focal therapy of intermediate-risk prostate cancer performed under MRgFUS is safe, with very encouraging two-year oncological and functional outcomes," they wrote.
